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and Related Death in Patients with Differentiated Thyroid
Carcinoma
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Division of Endocrine Surgery, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong,
Hong Kong SAR, China
ABSTRACT
Background. Differentiated thyroid cancer (DTC) survi-
vors are at increased risk of developing nonsynchronous
second primary malignancy (NSPM). This study aims to
examine possible risk factors leading to occurrence of
NSPM as well as risk factors leading to NSPM-related
death in patients with DTC.
Methods. Of the 1,106 patients with DTC managed at our
institution, 92 (8.3%) patients developed NSPM and 40
(3.6%) patients died of NSPM. All causes of death were
confirmed by medical record, autopsy report or death cer-
tificate. Clinicopathological variables were compared
between those without NSPM and with NSPM as well as
between those who died of NSPM and did not die of
NSPM. Significant variables on univariate analysis were
entered into a Cox proportional hazards model.
Results. The median latency period from diagnosis of
DTC to NSPM was 142.7 (range 16.8–511.0) months. For
occurrence of NSPM, age at DTC diagnosis C50 years old
[relative risk (RR) = 2.35], cumulative radioactive iodine
(RAI) activity 3.0–8.9 GBq (RR = 2.38), and external
local radiotherapy (ERT) (RR = 1.95) were significant risk
factors. For NSPM-related death, age at DTC diagnosis
C50 years old (RR = 3.32) and nonbreast cancer
(RR = 5.76) were significant risk factors.
Conclusions. NSPM accounted for 18.7% of all deaths in
DTC, but mortality was high (43.5%). Age at DTC diag-
nosis C50 years old, cumulative RAI activity 3.0–8.9 GBq,
and ERT were significant risk factors for occurrence of
NSPM, whereas age at DTC diagnosis C50 years old and
the diagnosis of nonbreast cancer were significant risk
factors for NSPM-related death.
Differentiated thyroid carcinoma (DTC) accounts for
over 90% of all follicular-derived thyroid malignancies and
is the commonest primary endocrine-related malignancy.
The age-adjusted incidence has doubled over the last
25 years in our locality, and a similar trend has been
observed elsewhere.1,2 Despite the increasing trend, the
disease-specific mortality remains low with overall 10-year
disease-specific survival above 90%.3 As a result, the great
majority of patients are expected to survive the disease and
treatment, but since this disease mostly affects relatively
young patients, the lifetime risk of developing a nonsyn-
chronous second primary malignancy (NSPM) poses
concerns.4 Previous studies found that, when all nonthy-
roidal cancer sites were considered, DTC survivors were at
significantly increased risk of developing NSPM when
compared with the general population.5–8 Specific cancer
sites reported to have increased incidence include breast,
stomach, salivary gland, colon, and bladder.5,9,10 Although
the exact reason or cause for this apparent risk increase
remains unclear, possible explanations include the effect of
ionizing radiation from radioactive iodine (RAI) and
external local radiotherapy (ERT), posttreatment surveil-
lance bias, common environmental factors, dietary factors,
and genetic predisposition.7,9,11,12 In addition to the
increased risk of developing NSPM, those with NSPM
were shown to have significantly worse overall survival
than those without NSPM.8 Furthermore, the majority of
DTC survivors with NSPM will eventually die of it.8 As a
result, a compulsory surveillance program for DTC survi-
vors has been proposed.5,7 However, it remains unknown
which factors and patients are more likely to develop
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NSPM and die of NSPM. Perhaps, gaining better knowl-
edge of these risk factors would be useful in future
planning of such surveillance program. It would allow
better selection or stratification of DTC survivors for can-
cer surveillance and would make the program more cost
effective. To our knowledge, there have been no studies
specifically focusing on which factors influence the risk of
developing and dying of NSPM. Studies so far have con-
centrated mainly on risk factors for DTC development and
DTC-related death and not on NSPM and related
death.3,13,14 Therefore, the aims of the present study were
to examine possible risk factors leading to occurrence of
NSPM as well as risk factors leading to NSPM-related
death in patients with DTC.
PATIENTS AND METHODS
From 1960 to 2009, 1,210 patients with DTC were
managed at our institution. After excluding 104 (8.6%)
patients with clinically occult microcarcinomas, there
were a total of 1,106 patients eligible for analysis. To
ensure an accurate and updated follow-up status of all
patients, a careful manual search of all patients’ status in
the territory-wide clinical management system (CMS) was
performed. The CMS is a computerized database linking
up all 41 public hospitals and provides inpatient medical
records corresponding to over 90% of inpatient bed days
in the region.15 Specific variables including latest date of
follow-up or date of death, date of birth, cause of death,
diagnosis date, and type of second nonthyroidal primary
malignancy were recorded from the CMS. All causes of
death were further confirmed by careful examination of
the medical record, autopsy report, and/or death certifi-
cate. Clinicopathological data and management details
relating to the DTC were prospectively collected since
1995.
The time to development of SPM was calculated from
date of DTC diagnosis to diagnosis date of the second
malignancy. SPM which occurred within 12 months from
date of DTC diagnosis was considered synchronous and
was excluded from analysis. NSPM was defined as second
malignancy that occurred over 12 months after date of
DTC diagnosis. For patients who developed two or more
nonthyroidal primary malignancies after DTC, only the
earliest occurred malignancy was recorded. Patients with
history of antecedent SPM (i.e., diagnosed [12 months
before DTC diagnosis) were excluded from the analysis.
Time at risk for NSPM was computed from date of DTC to
date of NSPM, date of death or date of last follow-up,
whichever came first. For those with NSPM, time at risk of
dying from it was computed from date of DTC to date of
death from NSPM or date of last follow-up, whichever
came first.
DTC Treatment Protocol
The management protocol for DTC remained unchanged
throughout the study period, and details were described
previously.16 Those with preoperative diagnosis of DTC
were offered total or near-total thyroidectomy (i.e., less
than 1 g of thyroid tissue remaining). Prophylactic central
neck dissection was not routinely performed until 2006.
Patients with one or more risk factors such as tumor size
[2 cm, lymph node metastasis, age[40 years, presence of
extrathyroidal extension, macroscopic postoperative resid-
ual disease in the neck, and/or distant metastasis were
considered for RAI ablation 8–10 weeks after thyroidec-
tomy by either T4 withdrawal or use of recombinant
thyroid-stimulating hormone (TSH). Diagnostic whole-
body 131I scans were performed approximately 6 months
after RAI therapy. Three gigabecquerels (GBq) or 80
millicuries (mCi) 131I was administered as standard abla-
tive dose, while subsequent RAI therapy involved 5.5 GBq
(or 150 mCi). Additional 5.5 GBq RAI therapy was
administered periodically at 4- to 6-month intervals until
uptake was no longer visible or disease progressed despite
treatment. The cumulative RAI dose or activity for each
individual patient was calculated. ERT was reserved for
those with extensive extrathyroidal tumor extension,
incomplete resection (R2), and/or extracapsular lymph
node metastasis. Although the above protocol was closely
followed throughout the study period, individual patient
preference was considered and respected. The present
study protocol was approved by the local institutional
review board.
Statistical Analysis
For comparison of dichotomous variables between
groups, chi-squared tests and Fisher’s exact tests were
used. Mann–Whitney U test was used for comparison of
continuous variables between groups. Those variables with
significance level p \ 0.05 on univariate analysis were
entered into the multivariate analysis. Regression analysis
was performed using the Cox proportional hazards model.
All statistical analyses were performed using SPSS version
11.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
After median follow-up of 104.33 (range 14.1–570.75)
months, there were 81 (7.3%) who died of DTC, 57 (5.1%)
who died of nonthyroidal malignancy, and 76 (6.9%) who
died of a medical or natural cause. Over the same period,
there were 170 (15.4%) patients who developed at least one
SPM. Of these, 78 patients developed SPM within
12 months of diagnosis of DTC (i.e., synchronous SPM)
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and 92 patients developed SPM more than 12 months after
diagnosis of DTC. For the purpose of the analysis, the
synchronous group (n = 78) was excluded. The median
latency period from DTC to NSPM was 142.7 (range
16.8–511.0) months. Therefore, there were 936 patients
who did not develop SPM (group A) and 92 who developed
NSPM (group B).
Table 1 presents a comparison of demographics, period
of DTC diagnosis, histological types of DTC, and stage of
DTC between group A and group B. Patients in group B
were significantly older at time of DTC diagnosis (48.0
versus 43.0 years, p \ 0.001), and there was a significantly
greater proportion of patients belonging to the C50 years
old age group (47.8% versus 34.6%, p \ 0.001). Sex and
histological types of DTC appeared similar between the
two groups. When the period of DTC diagnosis was
compared, there was a significant greater proportion of
patients belonging to group B before 1980 (29.3% versus
14.6%, p \ 0.001). Tumor stages of DTC appeared similar
between the two groups, although there was a tendency for
more advanced DTC in group B. As a result, there was a
significantly higher proportion of patients in group B
receiving RAI therapy (90.1% versus 72.8%, p = 0.003)
and ERT (16.3% versus 7.8%, p = 0.005).
Table 2 presents the Cox proportional hazards analysis
of risk factors for development of NSPM in DTC. Tumor
stage of DTC was also entered into the multivariate anal-
ysis because it almost reached significance with p = 0.071.
Age C50 years old, cumulative RAI activity 3.0–8.9, and
ERT emerged as independent risk factors for development
of NSPM in DTC. Both tumor stage of DTC and period of
DTC diagnosis did not emerge as significant risk factors on
multivariate analysis.
A further analysis was performed to evaluate which risk
factors determine the risk of dying from NSPM. After
median follow-up of 149.3 (range 19.6–531.1) months,
there were 40 (43.5%) patients who died of NSPM. As a
proportion of the total number of deaths, NSPM accounted
for 40/214 or 18.7%. Of the other 52 patients who did not
die of NSPM, 37 (71.2%) patients were still alive and free
of DTC and NSPM, 3 (5.8%) were free of DTC but not
NSPM, 2 (3.8%) were free of NSPM but not DTC, 2
(3.8%) died of metastatic DTC, and 8 (15.4%) died of a
medical or natural cause. All these patients were consid-
ered as those who did not die from NSPM (i.e., group II).
Table 3 presents a comparison of demographics, type of
second primary malignancies, histology of thyroid carci-
noma, and TNM stages between those who died of NSPM
TABLE 1 Comparison of
demographics, period of
diagnosis, histology of thyroid
carcinoma, and TNM stages
between those who did not
develop second primary
malignancy (SPM) (group A)
and those who did develop
nonsynchronous SPM (group B)
a Data available in 828 patients
in group A and 81 patients in
group B
DTC differentiated thyroid
carcinoma, TNM 6th edition
AJCC/UICC tumor–node–
metastasis staging system
Bold values mean P \ 0.05
Group A (n = 936) Group B (n = 92) p-Value
Median age at DTC diagnosis 43.0 (7.1–90.9) 48.0 (12.3–89.2) 0.005
Age at DTC diagnosis by groups (years) 0.011
\50 612 5.4) 48 (52.2)
C50 324 (34.6) 44 (47.8)
Sex 0.158
Male 186 (19.8) 24 (26.1)
Female 750 (80.1) 68 (73.9)
Period of DTC diagnosis \0.001
Before 1980 137 (14.6) 27 (29.3)
1980–1999 413 (44.1) 51 (55.4)
After 2000 386 (41.2) 14 (15.2)
Histological type of DTC 0.180
Papillary 747 (79.8) 68 (73.9)
Follicular 189 (20.2) 24 (26.1)
Stage of DTC by TNM 0.071
Stage I/II 664 (70.9) 58 63.0)
Stage III/IV 272 (29.1) 34 (37.0)
Cumulative RAI activity (GBq)a 0.003
None 225 (27.2) 8 (9.9)
3–8.9 573 (69.2) 70 (86.4)
C9.0 30 (3.6) 3 (3.7)
External local radiotherapy 0.005
No 863 (92.2) 77 (83.7)
Yes 73 (7.8) 15 (16.3)
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(group I) and those who did not die of NSPM (group II).
Patients in group I had significantly older median age at
time of DTC diagnosis (54.5 versus 45.0 years,
p = 0.020), but the proportion of patients belonging to the
C50 years old age group was similar in the two groups
(55.0% versus 42.3%, p = 0.227). Despite this conflicting
finding, age C 50 years old was entered into the multi-
variate analysis. Median age at NSPM diagnosis, latency
period from DTC to NSPM, period of DTC diagnosis,
histological types of DTC, tumor stages of DTC, cumula-
tive RAI activity, and ERT were similar between the two
groups. In terms of type or site of NSPM, breast cancer was
significantly more frequent in group II (36.5% versus 7.5%,
p = 0.001) whereas stomach cancer was more frequent in
group I (10.0% versus 0.0%, p = 0.033).
Table 4 presents the Cox proportional hazards analysis
of risk factors of dying from NSPM in patients with DTC.
Age, sex, breast cancer, and stomach cancer were entered
into the Cox proportional hazards analysis. Age C50 years
old [relative risk (RR) = 3.321, 95% confidence interval
(CI) 1.095–5.383] and breast cancer (RR = 0.174, 95% CI
0.050–0.608) emerged as independent factors for NSPM-
related survival. Breast cancer was associated with reduced
risk of NSPM-related death. Conversely, nonbreast cancer
was associated with increased risk of NSPM-related death
(RR = 5.758, 95% CI 1.645–20.149).
DISCUSSION
DTC is the commonest primary endocrine-related
malignancy. Despite its rising incidence, prognosis remains
excellent with overall 10-year disease-specific survival of
over 90%.3 As a result, the great majority are expected to
survive their disease and treatment. One previous study has
found that those who remain free of DTC recurrence have
the same life expectancy as the normal population.17
Although theoretically patients who survive long enough
and are cured of DTC would eventually develop or die of
nonthyroidal malignancy or other unrelated causes, it is
concerning to find that DTC survivors are at greater risk of
developing SPM than the normal population.5–8,18 Studies
have found that, when all cancer sites are considered, this
increase in risk ranged between 10% and 40%, depending
on study design and patient selection.5,6,8,18 A meta-anal-
ysis of 70,000 DTC survivors reported a 20% increase in
NSPM incidence.18 Possible contributing factors include
use of RAI therapy, ERT, common environmental risk
factors, genetic mutations, and surveillance bias.7,9,11,12
Since there is some evidence suggesting that this increased
risk of NSPM could possibly be related to the treatment for
DTC, more selective and restricted use of RAI therapy and
ERT in DTC has been advocated.19 The first part of our
analysis seems to support this hypothesis, with cumulative
RAI activity of 3.0–8.9 GBq having an increased relative
risk of 2.38 when compared with those who did not receive
any RAI therapy. Furthermore, those who received ERT for
DTC had increased relative risk of 1.95 when compared
with those who were not exposed to ERT. Given that the
decision for RAI and/or ERT was primarily based on tumor
stage, it was also entered into the multivariate Cox pro-
portional hazards analysis but did not emerge as an
independent risk factor. The authors believed the reason
why there was a significant difference in period of DTC
diagnosis between the two groups was because of the
TABLE 2 Cox proportional
hazards analysis of risk factors
for development of
nonsynchronous second primary
malignancy (NSPM) in
differentiated thyroid carcinoma
DTC differentiated thyroid
carcinoma, RAI radioactive
iodine or 131I, TNM 6th edition
AJCC/UICC tumor–node–
metastasis staging system
Bold values mean P \ 0.05
Covariate Relative risk 95% Confidence interval p-Value
Age at DTC diagnosis by groups (years)
\50 1
C50 2.345 1.327–4.144 0.003
Period of DTC diagnosis
Before 1980 1
1980–1999 1.301 0.705–2.398 0.400
After 2000 1.720 0.685–4.317 0.248
Stage of DTC by TNM
Stage I/II 1
Stage III/IV 1.575 0.878–2.827 0.128
Cumulative RAI activity (GBq)
\2.9 1
3–8.9 2.383 1.039–5.256 0.040
C9.0 2.062 0.496–8.174 0.328
External local radiotherapy
No 1
Yes 1.947 1.030–3.681 0.041
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selection bias of the study, as patients with longer follow-
up (i.e., diagnosed earlier) were more likely to develop
NSPM than those with shorter follow-up. However, after
adjusting for the effect of age, period of DTC diagnosis,
and stage of DTC, both RAI and ERT emerged as inde-
pendent factors for development of NSPM. However,
unlike one previous study, our study was not able to
establish a dose–effect relationship between cumulative
RAI activity and risk of NSPM development, because the
relative risk was not significant in the group which had
cumulative RAI activity C9.0 GBq.6 Perhaps, with a larger
patient population, this result might have been significant,
and so our study was underpowered in this respect. An
alternative explanation might have been related to the dose-
threshold phenomenon where the risk of RAI activity
C9.0 GBq far exceeded the dose threshold, imparting the
TABLE 3 Comparison of demographics, type of second primary malignancies, histology of thyroid carcinoma, and TNM stages between those
who did die of NSPM and those who did not
Died of SPM (n = 40) Did not die of SPM (n = 52) p-Value
Median age at DTC diagnosis (years) 54.5 (19.1–88.8) 45.0 (12.1–87.3) 0.020
Age at DTC diagnosis by groups (years) 0.227
\50 18 (45.0) 30 (57.7)
C50 22 (55.0) 22 (42.3)
Median age at NSPM diagnosis (years) 66.1 (22.7–94.2) 57.2 (28.8–87.7) 0.082
Median latency period from DTC to NSPM (months) 129.6 (16.8–357.97) 163.4 (18.9–511.0) 0.431
Sex 0.003
Male 17 42.5) 7 (13.5)
Female 23 (57.5) 45 (86.5)
Period of DTC diagnosis 0.708
Before 1980 11 (27.5) 16 (30.8)
1980–1999 24 (60.0) 27 (51.9)
After 2000 5 (12.5) 9 (17.3)
Histological type of DTC 0.244
Papillary 32 (80.0) 36 (69.2)
Follicular 8 (20.0) 16 (30.8)
Stage of DTC by TNM 0.480
Stage I/II 23 (57.5) 34 (65.4)
Stage III/IV 17 (42.5) 18 (34.6)
Cumulative RAI activity (GBq)a 0.881
None 4 (10.5) 4 (9.3)
3–8.9 33 (86.8) 37 (86.0)
C9.0 1 (2.6) 2 (4.7)
External local radiotherapy 0.400
No 8 (20.0) 7 (13.5)
Yes 32 (80.0) 45 (86.5)
Type/site of NSPMb
Breast 3 (7.5) 19 (36.5) 0.001
Colon 7 (17.5) 4 (7.7) 0.199
Lung 7 (17.5) 3 (5.8) 0.096
Stomach 4 (10.0) 0 (0.0) 0.033
Liver 3 (7.5) 1 (1.9) 0.313
Uterus 2 (5.0) 2 (3.8) 1.000
Non-Hodgkin lymphoma 2 (5.0) 1 (1.9) 0.578
a Data available in 81 patients
b Only nonsynchronous second primary malignancy with a total number C 3 are listed
DTC differentiated thyroid carcinoma, NSPM nonsynchronous second primary malignancy, TNM 6th edition AJCC/UICC tumor–node–
metastasis staging system
Bold values mean P \ 0.05
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same risk as RAI activity of 3.0–8.9 GBq. Age C50 years
old emerged as a significant risk factor for NSPM devel-
opment as well as a significant independent factor for
NSPM-related death. However, this was not a very sur-
prising result, as many of the population-based studies have
demonstrated a direct association between the incidence of
many nonthyroidal solid malignancies and age.20 This is
because cancer is a disease associated with aging and the
majority of cancer diagnoses and deaths occur in the older
population, particularly those aged [65 years old.20 The
clinical relevance of this finding is that patients aged
C50 years old with newly diagnosed DTC are probably not
only at increased risk of dying from DTC as previously
shown but are also at increased risk of developing and
dying from NSPM.3
In terms of overall survival of patients with DTC, after
median follow-up of 104.3 (range 14.1–570.8) months,
there were a total of 214 deaths. Of these, 81 (37.9%) died
of DTC, 57 (26.6%) died of nonthyroidal malignancy, and
76 (35.5%) died of a medical or natural cause. In other
words, over a third of deaths were still related to DTC
whereas only a fourth of deaths were related to nonthy-
roidal malignancy. If only NSPM was considered, it
accounted for only 40/214 or 18.7% of the total number of
deaths. This might seem a relatively small proportion, but
if one considers the fact that only 92 patients developed
NSPM during follow-up, the overall mortality from NSPM
was 40/92 or 43.5% whereas the overall mortality from
DTC was 81/1,106 or 7.3%.
Given the relatively high mortality in NSPM, the second
part of our analysis sought to examine which factors might
influence NSPM-related survival in DTC. As discussed
earlier, age at diagnosis of DTC C50 years old increased not
only the risk of NSPM development but also the risk of dying
from NSPM (RR = 3.32, 95% CI 1.10–5.38). This finding
concurs with the experience of many nonthyroidal malig-
nancies that increased age correlates with risk of cancer-
related death.20 However, it was interesting that the risk of
dying from NSPM was significantly associated with age at
DTC diagnosis and not age at NSPM diagnosis, although
there was a tendency for older patients diagnosed with
NSPM to die of it (p = 0.082). One possible explanation
might have been because age at DTC diagnosis also influ-
enced the decision for RAI and ERT, and so this might have
been an added effect from RAI and ERT. Nevertheless, both
cumulative RAI activity and ERT were not significant fac-
tors for NSPM-related deaths. Apart from age at DTC
diagnosis, breast and stomach cancers were also significant
factors influencing NSPM-related death. According to our
data, the diagnosis of breast cancer had a relative protective
effect regarding NSPM-related death relative to nonbreast
NSPM. Putting it in another way, patients with nonbreast
NSPM were at increased risk of dying from NSPM
(RR = 5.758, 95% CI 1.655–20.15). Of the 22 patients with
breast cancers, only 3 (13.6%) died of it, whereas of the 4
patients with stomach cancers, all 4 (100%) died of it. This
could simply be related to the fact that the prognosis of
breast cancer was significantly better than that of stomach
cancer, despite better disease understanding and increasing
treatment modalities.21 Interestingly, some studies have
found that DTC survivors are at increased risk for both types
of malignancy, because both the breast and stomach take up
and accumulate 131I and so are often exposed to a prolonged
period of ionizing radiation.5,9 However, due to the rela-
tively small number of NSPMs, our study was not able to
calculate the risk of these cancers relative to the background
risk in the general population. Although male sex did not
reach significance on multivariate Cox proportional hazards
analysis, it was somewhat interrelated with breast cancer, as
only 1 of the 22 breast cancer patients was male. Never-
theless, male sex is believed to be a poor prognostic factor
for both thyroidal and nonthyroidal malignancies.20
Given that age at DTC diagnosis C50 years old, cumu-
lative RAI activity of 3.0–8.9 GBq, and administration of
ERT were independent risk factors for NSPM development,
patients with one or more of these risk factors should be
considered for surveillance of carcinoma of breast, colon,
lung, and stomach. Regarding timing, this should start
around 5–10 years after the DTC diagnosis, as the median
latency period from DTC to NSPM development was
142.7 months or 11.9 years. Regular breast examination
and/or mammographic screening, annual or biennial gas-
troscopy and colonoscopy, and chest radiography would be
useful for early detection of these malignancies. However,
more specific recommendations would be difficult to make
TABLE 4 Cox proportional hazards analysis of risk factors for dying
of nonsynchronous second primary malignancy (NSPM) in differen-
tiated thyroid carcinoma
Covariate Relative risk 95% Confidence interval p-Value
Age at DTC diagnosis by groups (years)
\50 1
C50 3.321 1.095–5.383 0.002
Sex
Female 1
Male 1.808 0.898–3.638 0.097
Breast carcinoma as NSPM
No 1
Yes 0.174 0.050–0.608 0.006
Stomach carcinoma as NSPM
No 1
Yes 2.116 0.679–6.601 0.196
DTC differentiated thyroid carcinoma, NSPM nonsynchronous second
primary malignancy
Bold values mean P \ 0.05
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because of the retrospective nature of the analysis and the
relatively small number of NSPMs involved. Furthermore,
this was a single institution’s experience, and so the analysis
was subjected to a certain degree of institutional and referral
biases. The present study could be further improved if other
risk factors such as physical activity, lifestyle exposures,
and dietary factors were taken into consideration.22 Per-
haps, future studies could also assess the impact of these
risk factors on the risk of NSPM in DTC.
CONCLUSIONS
Although NSPM only accounted for 18.7% of all deaths
in patients with DTC, the risk of dying from it was high
(43.5%). Age at DTC diagnosis C50 years old, cumulative
RAI activity of 3.0–8.9 GBq, and ERT were significant
independent risk factors for development of NSPM. On
further analysis of risk factors for NSPM-related death, age
at DTC diagnosis C50 years old remained a significant risk
factor whereas the diagnosis of breast cancer was associ-
ated with a reduced risk of dying from NSPM.
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